HCPCS code J2357: Injection, Omalizumab, 5 mg

The dose and frequency of omalizumab are determined by the patient's body weight and their pre-treatment total serum IgE level, according to the manufacturer's dosing chart.

No. Omalizumab is strictly for chronic management of allergic conditions and is not indicated for acute bronchospasm or status asthmaticus.

Yes. Most Medicare Advantage and commercial insurers require prior authorization due to the high cost and specialty drug status of omalizumab.